

NEWS RELEASE

IX BIOPHARMA WINS “BEST CBD (SUBLINGUAL) EDIBLE” AWARD AT THE WORLD CBD AWARDS 2022

Singapore, 21 October 2022 – Specialty pharmaceutical company **iX Biopharma Ltd** (SGX:42C), is pleased to announce that its novel sublingual medicinal cannabidiol (“CBD”) wafer, Xativa™, has won the “Best CBD (Sublingual) Edible” award” at the 2022 World CBD Awards ceremony in Barcelona, Spain last night.

The awards ceremony is a highlight of the World CBD B2B Expo and Conference, and celebrates the best-in-class in the CBD and Hemp industry for their standards, excellence, and achievements by recognising companies that go the extra mile to make the industry a safe and respected place, and operate their business with integrity, transparency and ethics.

Products nominated for the awards undergo a rigorous judging process employing lab report results, research panel reports, physical testing, application, and supporting documents as well as an aesthetics and safety report. The benchmarks are thoroughly examined by an independent panel of qualified and respected scientists, physicians, and professionals who are experts in the CBD or Hemp industry.

On winning the award, **iX Biopharma Chief Commercial Officer Eva Tan**, said, “We were up against strong contenders from other sublinguals including tinctures for this award and we are proud that Xativa™ has risen above its competition to emerge at the top. The CBD industry is one of the fastest growing sectors, propelled by rising public demand and the rapidly changing perceptions about the therapeutic potential of the cannabis plant. This award affirms that Xativa™ is clearly differentiated in the market, and we are determined to leverage this momentum for sustainable growth.”

CBD is one of the primary non-psychoactive compounds found in the cannabis plant, and has garnered growing interest due to its safety and effectiveness in treating a vast spectrum of health issues. While its medicinal benefits are clear, most delivery forms available today suffer from the lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability to truly provide an effective therapeutic effect for users. iX Biopharma’s Xativa™ was developed to address this gap in the market.

Xativa™ leverages on iX Biopharma’s novel and patented WaferiX™ technology and is manufactured via the Group’s proprietary freeze-drying technique, the WaferiX™ matrix holding the active CBD molecules is designed to transport drug actives rapidly across the sublingual membrane into the blood



Jeremy Dalton, Director of Business Development at iX Syrinx Pty Ltd, iX Biopharma’s wholly-owned subsidiary, receiving the award on behalf of the Group

vessels for rapid absorption and faster therapeutic action. Furthermore, Xativa™ offers a fixed unit dose that is familiar to physicians, facilitating standardised prescription and precise dosing.

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma has developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The WaferiX delivery platform is particularly useful for drug repurposing which is a growing trend with a global market worth over US\$30 billion¹. Drug repurposing is where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk. Other than Wafermine, iX Biopharma's portfolio includes among others, medicinal cannabis, sildenafil and burprenorphine sublingual wafers.

Contact for media:

Eva Tan
Chief Commercial Officer
T: +65 6235 3212
E: eva.tan@ixbiopharma.com

Alvina Tan
Media & Investor Relations Consultant
T: +65 9787 7267
E: alvina.tan@arkadvisors.com.sg

¹ <https://www.intechopen.com/books/drug-repurposing-hypothesis-molecular-aspects-and-therapeutic-applications/drug-repurposing-dr-an-emerging-approach-in-drug-discovery>